AUG 14, 2016 10:24 AM PDT

Tumors use local food shortage against T-cells

Image Credit: Guilhem Vellut/Flickr

The microenvironment that supports a cancerous tumor also starves the immune cells the body sends in to destroy the cancer, scientists report.

The finding holds the potential to significantly boost the performance of breakthrough immunotherapy drugs.

Researchers at the University of Pittsburgh Cancer Institute showed that when immune T cells enter the tumor microenvironment, their mitochondria—which act as mini-factories inside cells, making energy and crucial reagents a cell needs to survive—begin to shrink and disappear, indicating that the T cell is out of fuel and can’t do its tumor-destroying job.

The work, reported in the journal Immunity, opens the door to several potential clinical approaches that could help keep T cells functioning and boost the body’s ability to fight cancer.

“Immunotherapy to stimulate the body’s immune system has increasingly become the way we treat people with aggressive cancers. It’s effective for a subset of patients, but the truth is that only about 20 to 40 percent of patients will respond to the treatment, and it is still unclear why,” says senior author Greg M. Delgoffe, assistant professor of immunology and member of the Tumor Microenvironment Center at UPCI, partner with UPMC CancerCenter.

“It’s a huge question in the cancer immunotherapy field, and we think we’ve found a big part of the answer.”

As tumors grow, they build a microenvironment, which develops its own blood supply and keeps the tumor thriving, protected, and voraciously consuming all available nutrients.

When T cells enter the microenvironment, it’s as if they’re “automobiles that suddenly had the emergency brake applied; they can’t keep driving,” explains Delgoffe. Immunotherapies, like those that target negative regulators on the T cell surface, take these brakes off. “However, what we’re discovering in many cases is that even though the brakes have been taken off, there isn’t any fuel in the tank,” Delgoffe says. Or—in scientific terms—the lack of mitochondria in the tumor-infiltrating T cells keeps them from functioning.

“This is an exciting discovery because we already have various strategies to ‘fill the fuel tank’ and support T cell function in the tumor microenvironment,” says Delgoffe.

In laboratory experiments and tests with mice, Delgoffe and his team found that when they boosted the mitochondria in the T cells, they were better able to clear the tumor.

Delgoffe is partnering with other scientists to test various mitochondria-boosting strategies, including using drugs that already have proven safe in humans, such as those for type 2 diabetes, to stimulate T cell metabolism. He’s also working with existing immunotherapy studies to further modify the T cells so that their metabolism functions better in the tumor microenvironment.

Partial funding came from the Sidney Kimmel Foundation for Cancer Research and the National Institutes of Health.

Source: University of Pittsburgh

This article was originally published on futurity.org.
About the Author
  • Futurity features the latest discoveries by scientists at top research universities in the US, UK, Canada, Europe, Asia, and Australia. The nonprofit site, which launched in 2009, is supported solely by its university partners (listed below) in an effort to share research news directly with the public.
You May Also Like
OCT 17, 2021
Cardiology
Flu Vaccination Significantly Reduces Risk of Cardiac Events
OCT 17, 2021
Flu Vaccination Significantly Reduces Risk of Cardiac Events
The flu has been associated with a significantly increased risk of a cardiac event like heart attack or stroke.
NOV 17, 2021
Microbiology
Large Flu Outbreak at the University of Michigan Draws CDC's Attention
NOV 17, 2021
Large Flu Outbreak at the University of Michigan Draws CDC's Attention
Every year, there is a flu outbreak, and the severity can depend on many factors, like what strain is circulating. Last ...
DEC 11, 2021
Health & Medicine
The Vaccinated Can Still Get Long COVID
DEC 11, 2021
The Vaccinated Can Still Get Long COVID
Those who suffer from long COVID have persistent or new symptoms that weren't present during acute infection with SA ...
JAN 04, 2022
Immunology
Scientists Win a Game of Bacterial Hide-And-Seek
JAN 04, 2022
Scientists Win a Game of Bacterial Hide-And-Seek
When infection strikes, antibiotics are the go-to solution to help patients regain control from the invading bacter ...
JAN 03, 2022
Cancer
Heating Up the Immune Response: Turning Cold Tumors Hot
JAN 03, 2022
Heating Up the Immune Response: Turning Cold Tumors Hot
Immune checkpoints are present on the surface of immune cells throughout the body.  Under normal conditions, they r ...
JAN 18, 2022
Drug Discovery & Development
Identifying Oncostatin M (OSM): One Protein's Role in Severe Asthma
JAN 18, 2022
Identifying Oncostatin M (OSM): One Protein's Role in Severe Asthma
Asthma is a chronic condition that is characterized by difficulty breathing, coughing, and wheezing which is caused, in ...
Loading Comments...